Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial - ACR Mee
نویسنده
چکیده
George Karpouzas , Tsutomu Takeuchi , Carter Thorne , Shihong Sheng , Xiaoming Li , Ravi Rao , Kaiyin Fei and Benjamin Hsu , Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, Janssen Research & Development, LLC, Spring House, PA, GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
منابع مشابه
Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...
متن کاملSirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
OBJECTIVES The safety and efficacy of sirukumab, an anti-interleukin-6 (IL-6) monoclonal antibody, were evaluated in a 2-part, placebo-controlled phase II study of patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS In Part A (proof-of-concept), 36 patients were randomised to placebo or sirukumab 100 mg every 2 weeks (q2w) through week 10, with crossover treat...
متن کاملNew Drugs Drug News
72 P&T® • February 2010 • Vol. 35 No. 2 NEW DRUGS Actemra For Rheumatoid Arthritis Tocilizumab (Actemra) has been approved for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor antagonist therapies. This interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody may be used alone, with methotrexate, or ...
متن کاملSirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
OBJECTIVES Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study (ClinicalTrials.gov identifier NCT01604343) evaluated the efficacy and safety of...
متن کاملSpotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease primarily affecting synovial joints and is characterized by persistent high-grade systemic inflammation. Proinflammatory cytokines, particularly interleukin-6 (IL-6), are of crucial importance in the pathogenesis of the disease, driving both joint inflammation and extra-articular comorbidities. Tocilizumab, a humanized IL-6 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017